CIN No. L24232PB1983PLC005426 GST No. 03AAACK6458M1ZB
D.L. No. 1800-OSP, 1804-B I.E. Code No. 1293001210

KWALITY PHARMACEUTICALS LIMITED

Regd. Office: Village Nag Kalan, Majitha Road, Amritsar - 143 601 (INDIA)

Phone : 91-8558820862 (Accounts)
: 91-8558820863 (Admin.)
: 91-9915743720 (Exports)
M.D. Mobile : 91-9814071215, 9814052314
E-mail : export@kwalitypharma.com
ramesh@kwalitypharma.com
Website : www.kwalitypharma.com

Date: November 12, 2026

To,
The Department of Corporate Services,
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street,
Mumbai - 400001

Subject: Outcome of Board Meeting held on Thursday, November 12, 2026 pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Ref: Scrip Code: 539997

This is to inform you that pursuant to Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), the Board of Directors of the Company, at its meeting held today, i.e., Thursday, November 12, 2026, inter alia, considered and approved the following matters :

1. **Approval of Unaudited Financial Results:**

   Considered and approved the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2026, along with the Limited Review Report issued by the Statutory Auditors thereon. A copy of the said Unaudited Financial Results, together with the Limited Review Report, is enclosed herewith as **"Annexure-I".**

2. **Resignation of Statutory Auditors:**

   Took note of the resignation of M/s. Vijay Mehra & Co., Chartered Accountants (Firm Registration No. 001051N), from the position of Statutory Auditors of the Company, with effect from November 12, 2026.

   There are neither any concerns raised by the resigning auditor with respect to the management of the Company nor any material reasons for the resignation other than those stated in the resignation letter.

   The details with respect to the resignation of the Statutory Auditors, as required under Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, are annexed herewith as **"Annexure-II."**

CIN No. L24232PB1983PLC005426 GST No. 03AAACK6458M1ZB
D.L. No. 1800-OSP, 1804-B I.E. Code No. 1293001210

KWALITY PHARMACEUTICALS LIMITED

Regd. Office: Village Nag Kalan, Majitha Road, Amritsar - 143 601 (INDIA)

Phone : 91-8558820862 (Accounts)
: 91-8558820863 (Admin.)
: 91-9915743720 (Exports)
M.D. Mobile : 91-9814071215, 9814052314
E-mail : export@kwalitypharma.com
ramesh@kwalitypharma.com
Website : www.kwalitypharma.com

3. **Appointment of Statutory Auditors to fill Casual Vacancy:**

Based on the recommendation of the Audit Committee, the Board of Directors approved the appointment of **M/s. B S R & Co. LLP, Chartered Accountants (Firm Registration No. 101248W/W-100022)**, as the Statutory Auditors of the Company to fill the casual vacancy caused by the resignation of **M/s. Vijay Mehra & Co., Chartered Accountants**, with effect from November 12, 2026, pursuant to Section 139(8) of the Companies Act, 2013.

The aforesaid appointment shall be subject to the approval of the Members of the Company at a General Meeting to be convened within three months of the recommendation of the Board of Directors, in accordance with the applicable provisions of the Companies Act, 2013. Upon such approval, the newly appointed Statutory Auditors shall hold office until the conclusion of the next Annual General Meeting of the Company.

The requisite details of the newly appointed Statutory Auditors, as required under Regulation 30 read with Schedule III of the SEBI Listing Regulations, are enclosed herewith as **"Annexure-III".**

The Disclosure will be made Available on the Company's Website https://www.kwalitypharma.com/investor_relations.php

The Board Meeting of the Company commenced at 10:30 a.m. and concluded at 12:35 p.m.

You are requested to take the above information on record

Yours Faithfully,

For KWALITY PHARMACEUTICALS LIMITED

RAMESH KUMAR
Managing Director
DIN: 00462656

CIN No. L24232PB1983PLC005426 GST No. 03AAACK6458M1ZB
D.L. No. 1800-OSP, 1804-B I.E. Code No. 1293001210

KWALITY PHARMACEUTICALS LIMITED

Regd. Office: Village Nag Kalan, Majitha Road, Amritsar - 143 601 (INDIA)

Phone : 91-8558820862 (Accounts)
: 91-8558820863 (Admin.)
: 91-9915743720 (Exports)
M.D. Mobile : 91-9814071215, 9814052314
E-mail : export@kwalitypharma.com
ramesh@kwalitypharma.com
Website : www.kwalitypharma.com

Management Discussion and Analysis — Q2 FY27

Kwality Pharmaceuticals Ltd. ("KPL") delivered a strong performance in Q2FY27, building on the momentum established in the first quarter, with robust revenue growth, significant margin expansion and continued progress across its regulatory, manufacturing and product development initiatives. The Company continued to strengthen its international presence, supported by an accelerating pace of product registrations and an expanding portfolio of complex and specialised formulations.

In Q2FY27, consolidated revenue grew 63% year-on-year to ₹181 crore from ₹111 crore in Q2FY26, registering an 11.7% sequential growth over ₹162 crore in Q1FY27. EBITDA margins expanded to 27.5% from 23.4% in Q2FY26, reflecting improved operating leverage and a favourable product mix. PAT doubled to ₹50 crore from ₹25 crore in the corresponding quarter last year, with PAT margins expanding to 16% from 13%. On a sequential basis, PAT margins also improved from 15.7% in Q1FY27 to 16%. Consequently, consolidated revenue for H1FY27 stood at ₹343 crore, reflecting sustained business momentum and strong execution.

Building on the improving business outlook and an accelerated pace of product registrations across key international markets, management has further revised its FY27 revenue guidance upwards to **₹720 crore+ from its earlier guidance of ₹700 crore**. The increased guidance reflects the growing contribution from newly registered products and the Company's ability to convert its expanding regulatory pipeline into commercial opportunities.

During the quarter, the Company acquired 4 acres of land adjacent to its existing Amritsar manufacturing campus for the development of **Unit 7, a mega general manufacturing facility**. The proposed facility is envisaged as a fully automated manufacturing complex comprising 4+ injectable lines and 6+ oral solid dosage (OSD) lines. This strategic expansion is aimed at strengthening the Company's manufacturing infrastructure, enhancing its capabilities across multiple dosage forms and creating the capacity required to support its long-term growth ambitions.

On the regulatory front, KPL received **EU-GMP certification from Hungary, a Class 1 European regulatory jurisdiction, for its Cephalosporin and Oncology manufacturing facilities**. This approval marks a significant advancement in the Company's regulatory footprint, further strengthening its credentials in highly regulated markets and enhancing its ability to pursue opportunities in complex and high-value pharmaceutical segments.

During the quarter, the Company continued to advance its global product development programme. Out of its 40-molecule Bioequivalence (BE) programme for global filings,



CIN No. L24232PB1983PLC005426 GST No. 03AAACK6458M1ZB
D.L. No. 1800-OSP, 1804-B I.E. Code No. 1293001210

KWALITY PHARMACEUTICALS LIMITED

Regd. Office: Village Nag Kalan, Majitha Road, Amritsar - 143 601 (INDIA)

Phone : 91-8558820862 (Accounts)
: 91-8558820863 (Admin.)
: 91-9915743720 (Exports)
M.D. Mobile : 91-9814071215, 9814052314
E-mail : export@kwalitypharma.com
ramesh@kwalitypharma.com
Website : www.kwalitypharma.com

the Company has successfully completed BE studies for 19 products, which are now ready for regulatory filings across international markets. The expanding pipeline, coupled with new product registrations secured in key markets, is expected to provide a strong foundation for sustained growth and wider market penetration.

The Company's oncology manufacturing expansion is progressing as scheduled, with completion anticipated by June 2027. Additionally, construction of the Hormone manufacturing facility has been completed, and the Company has initiated the process for its manufacturing licence audit, marking another important milestone in the expansion of its specialised manufacturing capabilities.

With a view to further leveraging its existing ophthalmic manufacturing capacities, the Company undertook audits through SGS towards ISO 13485 and CE MDR certification. During the period, KPL also launched five new products from its ophthalmic eye-drop manufacturing lines, expanding its product portfolio and creating additional opportunities for capacity utilisation and market penetration.

The Company's biologics programme continues to progress with strong execution, with ongoing development initiatives aimed at strengthening its presence in complex biological products. The programme remains an important component of KPL's long-term strategy to diversify its product portfolio and expand into specialised and higher-value therapeutic segments.

The Company has also continued to demonstrate significant improvement in working capital efficiency, supported by tighter inventory management and improved receivables discipline. Debtor days have reduced to 178 days in H1FY27 from 203 days in FY26, while inventory days have improved to 77 days from 111 days. Payable days stood at 126 days compared to 144 days in FY26. Consequently, the cash conversion cycle has improved to 130 days from 170 days in FY26 and 297 days in FY23, representing an improvement of 167 days over the last three years. This continued focus on working capital discipline is strengthening cash generation and enabling the Company to support its growing business requirements more efficiently.

In a further step towards strengthening its corporate governance and financial reporting framework, the Company has appointed **M/s. B S R & Co. LLP, Chartered Accountants as its Statutory Auditors**. The appointment is aligned with KPL's expanding international presence and its ambition to evolve into a global pharmaceutical company, with a continued focus on adopting robust governance practices and enhancing the quality and transparency of financial reporting.

With improving financial performance, an expanding regulatory footprint, a growing global product pipeline and strategic investments in manufacturing infrastructure, KPL remains focused on building a scalable and globally competitive pharmaceutical business.

KWALITY PHARMACEUTICALS LTD. NAG KALAN, MAJITHA ROAD, AMRITSAR INDIA

VIJAY MEHRA & CO.
CHARTERED ACCOUNTANTS
Head Office : D-351, Ranjit Avenue, Amritsar.

CA Amit Handa
F.C.A DISA (ICAI), LL.B, LL.M
(Partner)
9878887600

CA Ashish Raja
F.C.A. Dip. IFRS B.Com
(Partner)
9899032170

CA Radhika Goel
F.C.A , B.com (Hons.)
(Partner)
9915460831

*Ref:*_____

Date : 12/11/2026

INDEPENDENT AUDITOR'S REVIEW REPORT ON UNAUDITED STANDALONE FINANCIAL RESULTS OF THE COMPANY FOR QUARTER ENDED 30TH SEPTEMBER, 2026 AND YEAR TO DATE FROM 01st APRIL 2026 TO 30th SEPTEMBER 2026 PURSUANT TO THE REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS,2015
(AS AMENDED)

To,

The Board of Directors
Kwality Pharmaceuticals Limited.

1. We have reviewed the accompanying statement of standalone unaudited financial results of **Kwality Pharmaceuticals Limited ("the company") for the quarter ended on 30th September, 2026**, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).

2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34) prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Our responsibility is to issue a report on the Statement based on our review.

VIJAY MEHRA & CO. CHARTERED ACCOUNTANTS

VIJAY MEHRA & CO.
CHARTERED ACCOUNTANTS
Head Office : D-351, Ranjit Avenue, Amritsar.

CA Amit Handa
F.C.A DISA (ICAI), LL.B, LL.M
(Partner)
9878887600

CA Ashish Raja
F.C.A. Dip. IFRS B.Com
(Partner)
9899032170

CA Radhika Goel
F.C.A , B.com (Hons.)
(Partner)
9915460831

*Ref:*_____

Date : 12/11/2026

3. We conducted our review of the statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with applicable Indian Accounting Standards (" Ind AS") and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

For VIJAY MEHRA & CO.
Chartered Accountants

VIJAY MEHRA & CO. CHARTERED ACCOUNTANTS AMRITSAR

CA AMIT HANDA
Partner
M. No: 502400
FRN: 001051N
UDIN:- 26502400MGTDAG9334

Place: Amritsar
Date: 12-11-2026

VIJAY MEHRA & CO.
CHARTERED ACCOUNTANTS
Head Office : D-351, Ranjit Avenue, Amritsar.

CA Amit Handa
F.C.A DISA (ICAI), LL.B, LL.M
(Partner)
9878887600

CA Ashish Raja
F.C.A. Dip. IFRS B.Com
(Partner)
9899032170

CA Radhika Goel
F.C.A , B.com (Hons.)
(Partner)
9915460831

*Ref:*_____

Date : 12/11/2026

INDEPENDENT AUDITOR'S REVIEW REPORT ON THE UNAUDITED CONSOLIDATED FINANCIAL RESULTS OF THE COMPANY FOR QUARTER ENDED 30TH SEPTEMBER, 2026 AND YEAR TO DATE FROM 01st APRIL 2026 TO 30th SEPTEMBER 2026 PURSUANT TO THE REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 (AS AMENDED)

To,

The Board of Directors
Kwality Pharmaceuticals Limited.

1. We have reviewed the accompanying statement of Consolidated Unaudited Financial Results of **Kwality Pharmaceuticals Limited ("the Parent") and its subsidiary (the Parent and its subsidiary together referred to as "the Group"), and its share of the net profit/(loss) after tax and total comprehensive income / loss for the quarter ended on 30th September 2026** being submitted by the Parent Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).

2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with the Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of

VIJAY MEHRA & CO CHARTERED ACCOUNTANTS AMRITSAR

VIJAY MEHRA & CO.
CHARTERED ACCOUNTANTS
Head Office : D-351, Ranjit Avenue, Amritsar.

CA Amit Handa
F.C.A DISA (ICAI), LL.B, LL.M
(Partner)
9878887600

CA Ashish Raja
F.C.A. Dip. IFRS B.Com
(Partner)
9899032170

CA Radhika Goel
F.C.A , B.com (Hons.)
(Partner)
9915460831

*Ref:*_____ *Date :* 12/11/2026

making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities:

Kwality Pharmaceuticals Africa Limitada (Foreign subsidiary)

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement of consolidated unaudited financial results prepared in accordance with applicable Indian Accounting Standards ("IndAs") and other accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements). Regulations, 2015 , as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. The consolidated unaudited financial results includes the interim financial statements/financial information/ financial results of subsidiary which have not been reviewed/audited by us, whose interim financial statements/ financial information/ financial results reflect total Assets of Rs. **186.86 lacs** as at 30th September.2026 and revenue for the half year ended 5.50 lacs. The total Profit/(loss) after tax of Rs. **(0.26) Lacs** and total

VIJAY MEHRA & CO. ACCOUNTANTS AMRITSAR

VIJAY MEHRA & CO.
CHARTERED ACCOUNTANTS
Head Office : D-351, Ranjit Avenue, Amritsar.

CA Amit Handa
F.C.A DISA (ICAI), LL.B, LL.M
(Partner)
9878887600

CA Ashish Raja
F.C.A. Dip. IFRS B.Com
(Partner)
9899032170

CA Radhika Goel
F.C.A , B.com (Hons.)
(Partner)
9915460831

*Ref:*_____ *Date :* 12/11/2026

comprehensive income/(loss) of P.s. **(0.26) Lacs** for the period ended 30th September,2026 has been considered in the consolidated unaudited financial results. According to the information and explanations given to us by the Management, these interim financial statements/financial information/financial results are not material to the Group. Our conclusion on the Statement is not modified in respect of the above matter.

For VIJAY MEHRA & CO.
Chartered Accountants

CA AMIT HANDA
Partner
M. No: 502400
FRN: 001051N
UDIN:- 26502400VMRABL4113

VIJAY MEHRA & CO. CHARTERED ACCOUNTANTS AMRITSAR

Place: Amritsar
Date: 12-11-2026

"Annexure-1"

KWALITY PHARMACEUTICALS LIMITED
Regd.Office.:- VILLAGE NAGKALAN, MAJITHA ROAD, AMRITSAR – 143601
CIN No. :- L24232PB1983PLC005426; Phone no. :- 8558820862
Email Id:- ramesh@kwalitypharma.com; Website :- www.kwalitypharma.com

Standalone Statement of Assets and Liabilities as at 30th September, 2026

(₹ in lakhs)

	Particulars	As at 30th SEPT, 2026 (Unaudited)	As at 31ST March, 2026 (Audited)
I	**ASSETS**		
A	**Non-current assets**		
	(a) Property Plant and Equipments	15921.81	14851.59
	(b) Intangible assets	775.90	584.54
	(c) Capital work-in-progress	3254.61	1700.62
	(d) Deferred tax Assets	58.64	250.18
		20010.97	**17386.93**
	(e)Financial Assets:		
	(i) Investments	354.78	354.78
	(f) Other non-current assets	1605.76	1145.23
	Total Non-Current Assets (A)	21971.50	**18886.94**
B	**Current assets**		
	(a) Inventories	7368.19	7825.23
	(b) Financial Assets:		
	(i) Trade receivables	33620.16	28121.97
	(ii) Cash and Bank Balances	178.90	68.28
	(iii) Bank Balances other than (ii) above	328.80	285.59
	(iv) Other Current Financial Assets	1313.70	882.01
	(c) Other current assets	5345.84	3496.04
	Total Current Assets (B)	48155.59	**40679.11**
	TOTAL ASSETS (A+B)	70127.09	**59566.06**
II	**EQUITY AND LIABILITIES**		
A	**Equity**		
	(a) Share capital	1037.62	1037.62
	(b) Other Equity	37760.34	32299.62
	Total Equity (A)	38797.96	**33337.24**

B	**Non-current liabilities**		
	(a) Financial Liabilities		
	(i) Borrowings	3823.25	2940.02
	(b) Provisions-Non current	156.61	118.32
	(c) Deferred tax liabilities (net)	.00	.00
	(d) Other Non-Current Liabilities	1261.46	618.49
	Total Non- current liabilites (B)	5241.32	**3676.82**
C	**Current liabilities**		
	(a) Financial Liabilities		
	(i) Borrowings	10800.99	10106.04
	(ii) Trade payables		
	-Total outstanding dues of micro enterprises and small enterprises	2166.32	1916.25
	-Total outstanding dues of other than micro enterprises and small enterprises	9816.19	8252.41
	(iii) Other Current Financial liabilities	610.19	527.96
	(b) Other Current Liabilities	1620.03	890.32
	(c) Provisions-Current	40.05	39.30
	(d) Current Tax Liabilties (net)	1034.04	819.73
	Total Current liabilites (C)	26087.81	**22552.00**
	TOTAL EQUITY AND LIABILITIES (A+B+C)	70127.09	**59566.06**

FOR KWALITY PHARMACEUTICALS LIMITED

RAMESH KUMAR
Managing Director
DIN:00462656

KWALITY PHARMACEUTICALS LTD. MAGH KALAN, BYPASS ROAD, AMRITSAR INDIA

Date: 12-11-2026
Place: Amritsar

KWALITY PHARMACEUTICALS LIMITED
Regd.Office.:- VILLAGE NAGKALAN, MAJITHA ROAD, AMRITSAR – 143601
CIN No. :- L24232PB1983PLC005426; Phone no. :- 8558820862
Email Id:- ramesh@kwalitypharma.com; Website :- www.kwalitypharma.com

Standalone Financial Results for the quarter and half year ended 30th September, 2026

(₹ in lakhs) except EPS

Sr. No.	Particulars	Quarter Ended 30.09.2026 (Unaudited)	Quarter Ended 30.06.2026 (Unaudited)	Quarter Ended 30.09.2025 (Unaudited)	Half Year Ended 30.09.2026 (Unaudited)	Half Year Ended 30.09.2025 (Unaudited)	Year Ended 31.03.2026 (Audited)
I	Revenue from operations (Net)	18116.79	16235.22	11131.31	34352.01	22279.20	50305.89
II	Other income	77.09	62.27	89.72	139.36	127.29	285.86
III	Total Revenue (I+II)	18193.88	**16297.49**	**11221.03**	**34491.37**	**22406.50**	**50591.75**
IV	Expenses						
	(a) Cost of materials consumed	8168.18	8533.77	5404.56	16701.96	10402.60	24081.02
	(b) Purchases of stock-in-trade	677.73	47.06	101.76	724.79	899.66	1734.63
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-177.36	161.70	-17.63	-15.66	-10.19	27.77
	(d) Employee benefits expense	1880.56	1474.29	1331.33	3354.85	2546.60	5403.84
	(e) Finance Cost	299.49	266.06	284.21	565.55	560.21	1097.04
	(f) Depreciation and amortisation expense	535.75	499.17	495.58	1034.92	971.56	1979.43
	(g) Other expenses	2587.94	1916.28	1776.09	4504.22	3486.91	7235.82
	Total expenses (IV)	**13972.30**	**12898.33**	**9375.90**	**26870.63**	**18857.34**	**41559.54**
V	Profit/(Loss) from operations before Exceptional items and Tax (III-IV)	**4221.58**	**3399.15**	**1845.12**	**7620.73**	**3549.15**	**9032.21**
VI	Exceptional items	00	00	00	00	0.00	82.94
VII	Profit / (Loss) before Tax (V-VI)	**4221.58**	**3399.15**	**1845.12**	**7620.73**	**3549.15**	**8949.27**
VIII	Tax expense						
	(1) Current tax	1059.80	864.97	457.36	1924.77	893.25	2280.03
	(2) Deferred tax	220.04	-28.50	18.45	191.54	93.37	-88.70
	(3) Income tax relating to earlier years	39.32	00	-42.33	39.32	-42.33	23.29
IX	Profit/(Loss) after Tax (VII-VIII)	**2902.42**	**2562.68**	**1411.64**	**5465.10**	**2604.86**	**6734.66**
X	Other Comprehensive Income						
	(i) Items that will not be reclassified to profit or loss	-13.38	9.00	-13.09	-4.38	2.28	13.67
	(ii) Items that will be reclassified to profit or loss	00	00	00	00	00	00
	Total Other Comprehensive Income (net of tax)	**-13.38**	**9.00**	**-13.09**	**-4.38**	**2.28**	**13.67**
XI	Total Comprehensive Income for the period (IX+X)	**2889.04**	**2571.68**	**1398.55**	**5460.73**	**2607.15**	**6748.33**
XII	Paid up Equity Share Capital (Face value	1037.62	1037.62	1037.62	1037.62	1037.62	1037.62
XIII	Other Equity(excluding revaluation reserve)						32219.62
XIV	Earnings per equity share (Non annualised)						
	(1) Basic	27.97	24.70	13.60	52.67	25.10	64.90
	(2) Diluted	27.97	24.70	13.60	52.67	25.10	64.90

FOR KWALITY PHARMACEUTICALS LIMITED

RAMESH KUMAR
Managing Director
DIN: 00462656

KWALITY PHARMACEUTICALS LTD. NAGKALAN MAJITHA ROAD, AMRITSAR INDIA

Date:- 12-11-2026
Place:- Amritsar

KWALITY PHARMACEUTICALS LIMITED
Regd.Office.:- VILLAGE NAGKALAN, MAJITHA ROAD, AMRITSAR – 143601
CIN No. :- L24232PB1983PLC005426; Phone no. :- 8558820862
Email Id:- ramesh@kwalitypharma.com; Website :- www.kwalitypharma.com

Standalone Cash Flow Statement for half year ended 30th September, 2026

(₹ in lakhs)

		Half Year ended 30th September 2026 (Unaudited)		Half Year ended 30th September 2025 (Unaudited)	
A	**CASH FLOW FROM OPERATING ACTIVITIES**				
	Net Profit Before Tax		**7620.73**		**3549.15**
	Adjustments for non-cash items:				
	Depreciation &Amortisation	1034.92		971.56	
	Other Non-Cash Items	34.67		15.28	
	Adjustments for Finance cost:				
	Interest & Finance Charges	565.55		560.21	
	Adjustments for Investing activities:				
	(Profit)/loss on sale of Assets	.00		-59.74	
	Interest on investments	-7.82		-7.59	
			1627.32		1479.72
	Operating Profit before Working Capital Changes		**9248.05**		**5028.88**
	Adjustments for:				
	Decrease/(Increase) in Trade receivables	-5498.19		-944.50	
	Decrease/(Increase) in Inventories	457.04		-11.11	
	Adjustment for Bank Balances (Except Cash & Cash Equivalent)	-43.21		-7.60	
	Decrease/(Increase) in Other Current Assets	-1849.80		-736.72	
	Decrease/(Increase) in Other Current Financial Assets	-431.69		-6.83	
	Increase/(Decrease) in Trade Payables	1813.85		250.12	
	Increase/(Decrease) in Financial Current Liabilities	82.23		-59.42	
	Increase/(Decrease) in Other Current Liabilties	729.71		197.11	
	Increase/(Decrease) in Other Liabilities & Provisions			-182.33	
			-4740.05		-1501.29
	Cash generated from operations		**4508.00**		**3527.59**
	Less: Income Tax Paid(Net of Refunds)		1749.78		850.92
	Net Cash flow from Operating activities (A)		**2758.22**		**2676.67**
B	**CASH FLOW FROM INVESTING ACTIVITIES**				
	Purchase for Property,Plant and Equipment	-3850.49		-917.88	
	Proceeds from disposal of Property,Plant and Equipment	.00		161.43	
	Interest on investments	7.82		7.59	
	Increase/(Decrease) in Other Non-Current Liabilities(Property advance)	642.97		414.00	
	(Increase)/Decrease in Other Non-Current Assets(Property advance)	-460.52		303.35	
	Net Cash used in Investing activities (B)		-3660.22		**-31.52**
C	**CASH FLOW FROM FINANCING ACTIVITIES**				
	Proceeds of Borrowings	2718.86		738.50	
	Repayment of Borrowings	-1140.68		-938.92	
	Interest paid	-565.55		-560.21	
	Net Cash from financing activities (C)		**1012.63**		**-760.63**
	Net increase in cash & Cash Equivalents (A+B+C)		110.63		1884.53
	Opening Cash and Cash equivalents		68.28		1155.29
	Closing Cash and Cash equivalents		**178.90**		**3039.82**
	Cash & Cash Equivalents		**As on 30.09.2026**		**As on 31.09.2025**
	Cash in Hand		12.28		42.23
	Cash at Bank		166.62		2997.58
	Cash & Cash equivalents as stated in Financial Statements		**178.90**		**3039.82**

Date:- 12-11-2026
Place:- Amritsar

FOR KWALITY PHARMACEUTICALS LIMITED

RAMESH KUMAR
Managing Director
DIN: 00462656

KWALITY PHARMACEUTICALS LTD. NAGKALAN, MAJITHA ROAD, AMRITSAR INDIA

KWALITY PHARMACEUTICALS LIMITED
Regd.Office.:- VILLAGE NAGKALAN, MAJITHA ROAD, AMRITSAR, PANJAB – 143601
CIN :- L24232PB1983PLC005426; Phone no. :- 8558820862
Email Id:- ramesh@kwalitypharma.com; Website :- www.kwalitypharma.com

Consolidated Statement of Assets and Liabilities as at 30th September, 2026

(₹ in Lakhs)

	Particulars	As at 30th Sept 2026 (Unaudited)	As at 31st March 2026 (Audited)
I	**ASSETS**		
A	**Non-current assets**		
	(a) Property Plant and Equipment	16042.21	14972.59
	(b) Intangible assets	775.90	584.54
	(c) Capital work-in-progress	3254.61	1700.62
	(d) Deferred tax Assets	58.64	250.18
		20131.37	**17507.93**
	(e)Financial Assets:		
	(i) Investments	.00	.00
	(f) Other non-current assets	1605.76	1145.23
	Total Non-current Assets (A)	**21737.12**	**18653.16**
B	**Current assets**		
	(a) Inventories	7369.74	7825.23
	(b) Financial Assets:		
	(i) Trade receivables	33503.65	28005.24
	(ii) Cash and Bank Balances	182.84	73.64
	(iii) Bank Balances other than (ii) above	328.80	285.59
	(iv) Other Current Financial Assets	1313.70	882.01
	(c) Other current assets	5345.84	3496.04
	Total Current Assets (B)	**48044.57**	**40567.75**
	TOTAL ASSETS (A+B)	**69781.69**	**59220.91**
II	**EQUITY AND LIABILITIES**		
A	**Equity**		
	(a) Share capital	1037.62	1037.62
	(b) Other Equity	37582.54	32121.94
	Total Equity attributable to Equity Holders of the company	38620.16	33159.56
	(c) Non Controlling Interests	- 167.59	- 167.47
	Total Equity (A)	**38452.56**	**32992.09**

KWALITY PHARMACEUTICALS LTD. MAJITHA RD. AMRITSAR INDIA

B	**Non-current liabilities**		
	(a) Financial Liabilities		
	(i) Borrowings	3823.25	2940.02
	(b) Provisions-Non current	156.61	118.32
	(c) Deferred tax liabilities (net)	.00	.00
	(d) Other Non-Current Liabilities	1261.46	618.49
	Total Non- current liabilities (B)	**5241.32**	**3676.82**
C	**Current liabilities**		
	(a) Financial Liabilities		
	(i) Borrowings	10800.99	10106.04
	(ii) Trade payables		
	-Total outstanding dues of micro enterprises and small enterprises	2166.32	1916.25
	-Total outstanding dues of other than micro enterprises and small enterprises	9816.19	8252.41
	(iii) Other Current Financial liabilities	610.19	527.96
	(b) Other Current Liabilities	1620.03	890.32
	(c) Provisions-Current	40.05	39.30
	(d) Current Tax Liabilities (net)	1034.04	819.73
	Total Current liabilities (C)	**26087.81**	**22552.00**
	TOTAL EQUITY AND LIABILITIES (A+B+C)	**69781.69**	**59220.91**

FOR KWALITY PHARMACEUTICALS LIMITED

RAMESH KUMAR
Managing Director
DIN: 00462659

KWALITY PHARMACEUTICALS LTD. KALITA ROAD AMRITSAR INDIA

Date:- 12-11-2026
Place:- Amritsar

KWALITY PHARMACEUTICALS LIMITED
Regd.Office.:- VILLAGE NAGKALAN, MAJITHA ROAD, AMRITSAR, PUNJAB – 143601
CIN No. :- L24232PB1983PLC005426; Phone no. :- 8558820862
Email Id:- ramesh@kwalitypharma.com; Website :- www.kwalitypharma.com

Consolidated Financial Results for the quarter and half year ended 30th September 2026

(₹ in lakhs) except EPS

Sr. No.	Particulars	Quarter Ended 30.09.2026 (Unaudited)	Quarter Ended 30.06.2026 (Unaudited)	Quarter Ended 30.09.2025 (Unaudited)	Half Year Ended 30.09.2026 (Unaudited)	Half Year Ended 30.09.2025 (Unaudited)	Year Ended 31.03.2026 (Audited)
I	Revenue from operations (Net)	18122.29	16235.22	11105.10	34357.51	22253.00	50308.34
II	Other income	77.09	62.27	89.72	139.36	127.29	285.86
III	**Total Revenue (I+II)**	18199.38	**16297.49**	**11194.82**	**34496.86**	**22380.29**	**50594.19**
IV	Expenses						
	(a) Cost of materials consumed	8168.18	8533.77	5404.56	16701.96	10402.60	24081.02
	(b) Purchases of stock-in-trade	683.84	47.06	101.76	730.90	899.66	1734.63
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-178.91	161.70	-43.83	- 17.21	-36.40	27.77
	(d) Employee benefits expense	1880.86	1474.39	1331.27	3355.26	2546.75	5404.26
	(e) Finance Cost	299.49	266.06	284.21	565.55	560.21	1097.04
	(f) Depreciation and amortisation expense	536.05	499.47	495.95	1035.52	972.41	1981.04
	(g) Other expenses	2588.09	1916.33	1775.84	4504.42	3487.22	7236.28
	Total expenses (IV)	**13977.60**	**12898.78**	**9349.77**	**26876.39**	**18832.45**	**41562.04**
V	Profit before share of profit of equity accounted investees, exceptional items and	**4221.77**	**3398.70**	**1845.05**	**7620.48**	**3547.84**	**9032.16**
VI	Share of profit/(loss) of associates and joint ventures accounted for using equity method (net of income tax)	0.00	0.00	0.00	0.00	0.00	0.00
VII	Profit before exceptional items and tax	**4221.77**	**3398.70**	**1845.05**	**7620.48**	**3547.84**	**9032.16**
VIII	Exceptional items	.00	.00	.00	.00	.00	82.94
IX	Profit / (Loss) before Tax (VII-VIII)	**4221.77**	**3398.70**	**1845.05**	**7620.48**	**3547.84**	**8949.21**
X	Tax expense:						
	(1) Current tax	1059.80	864.97	457.36	1924.77	893.25	2280.03
	(2) Deferred tax	220.04	-28.50	18.45	191.54	93.37	- 88.70
	(3) Income tax relating to earlier years	39.32	.00	-42.33	39.32	-42.33	23.29
	(4) MAT Credit (Entitlement)/Utilised	.00	.00		0.00		0.00
XI	Profit/(Loss) after Tax (IX-X)	**2902.62**	**2562.23**	**1411.57**	**5464.85**	**2603.55**	**6734.60**
XII	Other Comprehensive Income						
	(i) Items that will not be reclassified subsequently to profit or loss						
	Remeasurement of defined benefit plans(net Tax)	-13.38	9.00	-13.09	- 4.38	2.28	13.67
	(ii) Items that will be reclassified to profit or loss:						
	Exchange differences in translating financial statements	.00	.00	- 10	.00	- 36	- 23
	tax)	**-13.38**	**9.00**	**-13.18**	**- 4.38**	**1.93**	**13.44**
	Total Comprehensive Income for the period (XI+XII)	**2889.24**	**2571.23**	**1398.39**	**5460.47**	**2605.47**	**6748.04**

Ramesh

XIII	Profit/(loss) attributable to:						
	a) Owners of the Company	2902.52	2562.45	1411.61	5464.97	2604.19	6734.63
	b) Non-controlling interests	.09	-.22	-.04	-.13	-.65	-.03
XIV	Other comprehensive income attributable to:						
	a) Owners of the Company	-13.38	9.00	-13.18	-4.38	1.93	13.44
	b) Non-controlling interests	-		-		-	
XV	Total comprehensive income attributable to:						
	a) Owners of the Company	2889.14	2571.45	1398.42	5460.60	2606.12	6748.07
	b) Non-controlling interests	.09	-.22	-.04	-.13	-.65	-.03
XVI	Paid up Equity Share Capital (Face value	1037.62	1037.62	1037.62	1037.62	1037.62	1037.62
XVII	Other Equity(excluding revaluation reserve)					-	32041.94
XVIII	Earnings per equity share (Non annualised) (In Rs.)						
	(1) Basic	27.93	24.69	13.60	52.63	25.09	64.90
	(2) Diluted	27.93	24.69	13.60	52.63	25.09	64.90

FOR KWALITY PHARMACEUTICALS LIMITED

Date:- 12-11-2026
Place:- Amritsar

RAMESH KUMAR
Managing Director
DIN: 00462656

KWALITY PHARMACEUTICALS LTD. AMRITSAR INDIA

KWALITY PHARMACEUTICALS LIMITED

Consolidated Cash Flow Statement for half year ended 30th September, 2026

(₹ in lakhs)

		Half Year ended 30th September 2026 (Unaudited)		Half Year ended 30th September 2025 (Unaudited)	
A	**CASH FLOW FROM OPERATING ACTIVITIES**				
	Net Profit Before Tax		**7620.48**		**3547.84**
	Adjustments for non-cash items:				
	Depreciation	1035.52		972.41	
	Other Non-Cash Items	34.67		14.92	
	Adjustments for Finance cost:				
	Interest & Finance Charges	565.55		560.21	
	Adjustments for Investing activities:				
	(Profit)/loss on sale of Assets	.00		-59.74	
	Interest on investments	-7.82		-7.59	
			1627.92		1480.21
	Operating Profit before Working Capital Changes		**9248.39**		**5028.05**
	Adjustments for:				
	Decrease/(Increase) in Trade receivables	-5498.41		-918.29	
	Decrease/(Increase) in Inventories	455.48		-37.32	
	Adjustment for Bank Balances (Except Cash & Cash Equivalent)	-43.21		-7.60	
	Decrease/(Increase) in Other Current Assets	-1849.80		-736.72	
	Decrease/(Increase) in Other Current Financial Assets	-431.69		-6.83	
	Increase/(Decrease) in Trade Payables	1813.85		250.12	
	Increase/(Decrease) in Other Current Financial Liabilities	82.23		-59.42	
	Increase/(Decrease) in Other Current Liabilties	729.71		197.11	
	Increase/(Decrease) in Other Liabilities & Provisions			-182.33	
			-4741.83		-1501.29
	Cash generated from operations		**4506.57**		**3526.76**
	Less: Income Tax Paid(Net of Refunds)		1749.78		850.92
	Net Cash flow from Operating activities (A)		**2756.79**		**2675.84**
B	**CASH FLOW FROM INVESTING ACTIVITIES**				
	Purchase for Property,Plant and Equipment	-3850.49		-917.88	
	Proceeds from disposal of Property,Plant and Equipment	.00		199.70	
	Interest on FDR	7.82		7.59	
	Increase/(Decrease) in Other Non-Current Liabilities(Property advance)	642.97		414.00	
	(Increase)/Decrease in Other Non-Current Assets(Property advance)	-460.52		303.35	
	Net Cash used in Investing activities (B)		**-3660.22**		**6.76**
C	**CASH FLOW FROM FINANCING ACTIVITIES**				
	Proceeds from Borrowings	2718.86		738.50	
	Repayments of Borrowings	-1140.68		-938.92	
	Interest paid	-565.55		-560.21	
	Net Cash from financing activities (C)		**1012.63**		**-760.63**
	Net increase in cash & Cash Equivalents (A+B+C)		109.20		1921.98
	Opening Cash and Cash equivalents		73.64		1202.02
	Closing Cash and Cash equivalents		**182.84**		**3123.99**
	Cash & Cash Equivalents		**As on 30.09.2026**		**As on 30.09.2025**
	Cash in Hand		12.75		43.08
	Cash at Bank		170.09		3080.92
	Cash & Cash equivalents as stated in Financial Statements		**182.84**		**3123.99**

Date:- 12-11-2026
Place:- Amritsar

FOR KWALITY PHARMACEUTICALS LIMITED

RAMESH KUMAR
Managing Director
DIN: 00462656

KWALITY PHARMACEUTICALS LTD. AMRITSAR INDIA

VIJAY MEHRA & CO.
CHARTERED ACCOUNTANTS
Head Office : D-351, Ranjit Avenue, Amritsar.

CA Amit Handa
F.C.A DISA (ICAI), LL.B, LL.M
(Partner)
9878887600

CA Ashish Raja
F.C.A. Dip. IFRS B.Com
(Partner)
9899032170

CA Radhika Goel
F.C.A , B.com (Hons.)
(Partner)
9915460831

*Ref:*_____

Date : 12/11/2026

"Annexure – II"

Date: 12th November, 2026

To,
The Board of Directors
Kwality Pharmaceuticals Limited
Village Nag Kalan, Majitha Road,
Amritsar, Punjab – 143601.

Subject: Resignation from the office of Statutory Auditors of Kwality Pharmaceuticals Limited

Dear Sir(s),

This is to inform you that due to our pre-occupation in other assignments, we are not in a position to devote our time to the affairs of the Company. Accordingly, we hereby tender our resignation from the office of Statutory Auditors of the Company with effect from 12th November 2026.

We further confirm that, prior to tendering this resignation, we have completed the Limited Review of the unaudited standalone and consolidated financial results of the Company for the quarter and half year ended 30th September 2026 and have issued our Limited Review Report dated 12th November 2026.

In compliance with the applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with the SEBI Master Circular dated 30th January, 2026, we are enclosing herewith the requisite information in the prescribed format as Annexure-I.

Thanking you,

Yours faithfully,

For Vijay Mehra & Co.
Chartered Accountants
Firm Registration No.: 001051N

Amit Handa
Partner
Membership No.: 502400
Place: Amritsar

VIJAY MEHRA & CO. CHARTERED ACCOUNTANTS AMRITSAR

Enclosure: Annexure-I

VIJAY MEHRA & CO.
CHARTERED ACCOUNTANTS
Head Office : D-351, Ranjit Avenue, Amritsar.

CA Amit Handa
F.C.A DISA (ICAI), LL.B, LL.M
(Partner)
9878887600

CA Ashish Raja
F.C.A. Dip. IFRS B.Com
(Partner)
9899032170

CA Radhika Goel
F.C.A , B.com (Hons.)
(Partner)
9915460831

*Ref:*_____

Date : 12/01/2026

ANNEXURE-I

Details as per SEBI master circular HO/49/14/14(7)2025-CFD-POD2/1/3762/2026 dated January 30, 2026.

S.No.	Particulars	Details
1	Name of the listed entity	Kwality Pharmaceuticals Limited
2	Details of the statutory auditor: a. Name: b. Address: c. Phone number: d. Email:	 M/s. Vijay Mehra & Co., Chartered Accountants. Head Office: D-351, Ranjit Avenue, Amritsar 9878887600 vmc.gst@gmail.com
3	Details of association with the listed entity: a. Date on which the statutory auditor was appointed b. Date on which the term of the statutory auditor was scheduled to expire c. Prior to resignation, the latest audit report/limited review report submitted by the auditor and date of its submission	 Appointed on 24th September 2024 at the 41st Annual General Meeting of the Company held in financial year 2024-25. Until the conclusion of 46th AGM i.e. financial year 2028-29. Limited Review Report on the unaudited standalone and consolidated financial results of the Company for the quarter and half year ended 30th September 2026, dated 12th November 2026.
4	Detailed reasons for resignation	Due to Pre-occupation in other assignments
5	In case of any concerns, efforts made by the auditor prior to resignation (including approaching the Audit Committee/Board of Directors along with the date of communication made to the Audit Committee/Board of Directors)	Not Applicable

VIJAY MEHRA & CO. CHARTERED ACCOUNTANTS AMRITSAR

VIJAY MEHRA & CO.
CHARTERED ACCOUNTANTS
Head Office : D-351, Ranjit Avenue, Amritsar.

CA Amit Handa
F.C.A DISA (ICAI), LL.B, LL.M
(Partner)
9878887600

CA Ashish Raja
F.C.A. Dip. IFRS B.Com
(Partner)
9899032170

CA Radhika Goel
F.C.A , B.com (Hons.)
(Partner)
9915460831

Ref: _____ ***Date :*** _____

6	In case the information requested by the auditor was not provided, then following shall be disclosed: a. Whether the inability to obtain sufficient appropriate audit evidence was due to a management-imposed limitation or circumstances beyond the control of the management. b. Whether the lack of information would have significant impact on the financial statements/results. c. Whether the auditor has performed alternative procedures to obtain appropriate evidence for the purposes of audit/limited review as laid down in SA 705 (Revised) d. Whether the lack of information was prevalent in the previous reported financial statements/results. If yes, on what basis the previous audit/limited review reports were issued.	Not Applicable
7	Any other facts relevant to the resignation:	Not Applicable

DECLARATION

1. We hereby confirm that the information given in this letter and its attachments is correct and complete.
2. We hereby confirm that there is no other material reason other than those provided above for our resignation.

For Vijay Mehra & Co.
Chartered Accountants
Firm Registration No.: 001051N

Amit Handa
Partner
Membership No.: 502400

Place: Amritsar
Date: 12-11-2026

CIN No. L24232PB1983PLC005426 GST No. 03AAACK6458M1ZB
D.L. No. 1800-OSP, 1804-B I.E. Code No. 1293001210
KWALITY PHARMACEUTICALS LIMITED
Regd. Office: Village Nag Kalan, Majitha Road, Amritsar - 143 601 (INDIA)

Phone : 91-8558820862 (Accounts)
: 91-8558820863 (Admin.)
: 91-9915743720 (Exports)
M.D. Mobile : 91-9814071215, 9814052314
E-mail : export@kwalitypharma.com
ramesh@kwalitypharma.com
Website : www.kwalitypharma.com

"Annexure-II"

Information as required under Regulation 30 and Schedule III of the SEBI LODR Regulations read with SEBI Master Circular SEBI/ HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026:

Resignation of Statutory Auditors

Particulars	**Details**
Name of the Auditor	M/s Vijay Mehra & Co., Chartered Accountants (FRN: 001051N)
Reason for Change viz. ~~appointment~~, resignation, ~~removal, death or otherwise~~	Resignation. The detailed reason for resignation is mentioned in the enclosed resignation letter dated 12th November 2026.
Date of ~~appointment/reappointment~~/cessation (as applicable)	Resigned with effect from 12th November 2026
Terms of appointment	Not Applicable
Brief Profile	Not Applicable
Disclosure of relationship Between Directors (in case of appointment of a director)	Not Applicable

KWALITY PHARMACEUTICALS LTD. NAG KALAN, MAJITHA ROAD, AMRITSAR INDIA

CIN No. L24232PB1983PLC005426 GST No. 03AAACK6458M1ZB
D.L. No. 1800-OSP, 1804-B I.E. Code No. 1293001210

KWALITY PHARMACEUTICALS LIMITED

Regd. Office: Village Nag Kalan, Majitha Road, Amritsar - 143 601 (INDIA)

Phone : 91-8558820862 (Accounts)
: 91-8558820863 (Admin.)
: 91-9915743720 (Exports)
M.D. Mobile : 91-9814071215, 9814052314
E-mail : export@kwalitypharma.com
ramesh@kwalitypharma.com
Website : www.kwalitypharma.com

"Annexure-III"

Information as required under Regulation 30 and Schedule III of the SEBI LODR Regulations read with SEBI Master Circular SEBI/ HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026:

Appointment of Statutory Auditor

Particulars	**Details**
Name of the Auditor	**M/s. B S R & Co. LLP, Chartered Accountants**
Reason for Change viz. appointment, ~~re-appointment, resignation, removal, death or otherwise~~	Appointment of M/s. B S R & Co. LLP, Chartered Accountants (Firm Registration No. 101248W/W-100022) as Statutory Auditors of the Company to fill the casual vacancy caused by the resignation of M/s. Vijay Mehra & Co. the existing Statutory Auditors.
Date of appointment/~~reappointment/ cessation~~ (as applicable) & term of appointment/~~re-appointment~~	November 12, 2026, subject to the approval of Members of the Company. M/s. B S R & Co. LLP shall hold the office until the conclusion of the 44th Annual General Meeting.
Brief Profile	M/s. B S R & Co. was constituted on 27 March 1990 as a partnership firm and was thereafter converted into limited liability partnership i.e. B S R & Co. LLP, on 14 October 2013. The registration no. of the firm is 101248W/W-100022. The registered office of the firm is at 14th Floor, Central B Wing and North C Wing, Nesco IT Park 4, Nesco Centre, Western Express Highway, Goregaon (East), Mumbai- 400063. B S R & Co. LLP is a member entity of B S R & Affiliates, a network registered with the Institute of Chartered Accountants of India. The firm has over 4000 staff and 170+ Partners and has offices across 14 locations. The firm audits various companies listed on stock exchanges in India including companies in the Pharmaceutical sector.
Disclosure of relationship Between Directors (in case of appointment of a director)	Not Applicable.

KWALITY PHARMACEUTICALS LTD. NAG KALAN MAJITHA ROAD AMRITSAR INDIA

CIN No. L24232PB1983PLC005426 GST No. 03AAACK6458M1ZB
D.L. No. 1800-OSP, 1804-B I.E. Code No. 1293001210

KWALITY PHARMACEUTICALS LIMITED

Regd. Office: Village Nag Kalan, Majitha Road, Amritsar - 143 601 (INDIA)

Phone : 91-8558820862 (Accounts)
: 91-8558820863 (Admin.)
: 91-9915743720 (Exports)
M.D. Mobile : 91-9814071215, 9814052314
E-mail : export@kwalitypharma.com
ramesh@kwalitypharma.com
Website : www.kwalitypharma.com

Notes:

1) The above financial results are prepared in accordance with the Indian Accounting Standards (Ind AS) as applicable and guidelines issued by the Securities and Exchange Board of India("SEBI"). The IndAS are prescribed under section 133 of the Act read with Rules,2015 and the Companies (Indian Accounting Standards) (Amendment) Rules,2016.

2) The unaudited Financial Results were reviewed by the Audit Committee and taken on record and approved by the Board of Directors at their meeting held on 12th November 2026.

3) As required under Regulation 33 of the SEBI(LODR) Regulations, 2015, the Statutory Auditors have issued Limited Review Reports on the aforesaid unaudited financial results for the quarter and half year ended 30th September,2026, which were also approved by the Audit Committee and the Board at their meeting held on Thursday, 12th November 2026.

4) The consolidated accounts have been prepared as per Indian Accounting Standard (IND AS) 110 on consolidated financial statements.

5) List of Subsidiary as on 30th September, 2026 is as under:

Name of Entity	Relationship	Country of Incorporation	% of ownership
Kwality Pharmaceuticals Africa, Limitada	Subsidiary	Africa	51%

6) Figures of Previous Year/Period have been regrouped /recast wherever necessary, in order to make them comparable.

7) The company is primarily engaged in the business of Pharmaceuticals which is single reportable segment for the quarter and half year ended 30th September 2026 in accordance with Ind AS 108 -" Operating Segment" and hence no separate segment reporting is given.

For Kwality Pharmaceuticals Limited

Date: 12/11/2026
Place: Amritsar

RAMESH KUMAR
MANAGING DIRECTOR
DIN: 00462656